This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1ld8

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1ld8.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:1ld8.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1ld8| PDB=1ld8 | SCENE= }}
{{STRUCTURE_1ld8| PDB=1ld8 | SCENE= }}
-
'''Co-crystal structure of Human Farnesyltransferase with farnesyldiphosphate and inhibitor compound 49'''
+
===Co-crystal structure of Human Farnesyltransferase with farnesyldiphosphate and inhibitor compound 49===
-
==Overview==
+
<!--
-
A series of macrocyclic 3-aminopyrrolidinone farnesyltransferase inhibitors (FTIs) has been synthesized. Compared with previously described linear 3-aminopyrrolidinone FTIs such as compound 1, macrocycles such as 49 combined improved pharmacokinetic properties with a reduced potential for side effects. In dogs, oral bioavailability was good to excellent, and increases in plasma half-life were due to attenuated clearance. It was observed that in vivo clearance correlated with the flexibility of the molecules and this concept proved useful in the design of FTIs that exhibited low clearance, such as FTI 78. X-ray crystal structures of compounds 49 and 66 complexed with farnesyltransferase (FTase)-farnesyl diphosphate (FPP) were determined, and they provide details of the key interactions in such ternary complexes. Optimization of this 3-aminopyrrolidinone series of compounds led to significant increases in potency, providing 83 and 85, the most potent inhibitors of FTase in cells described to date.
+
The line below this paragraph, {{ABSTRACT_PUBMED_12036349}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 12036349 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_12036349}}
==About this Structure==
==About this Structure==
Line 32: Line 36:
[[Category: Pftase]]
[[Category: Pftase]]
[[Category: Ra]]
[[Category: Ra]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 23:48:26 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jul 2 12:29:06 2008''

Revision as of 09:29, 2 July 2008

Image:1ld8.png

Template:STRUCTURE 1ld8

Co-crystal structure of Human Farnesyltransferase with farnesyldiphosphate and inhibitor compound 49

Template:ABSTRACT PUBMED 12036349

About this Structure

1LD8 is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.

Reference

3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency., Bell IM, Gallicchio SN, Abrams M, Beese LS, Beshore DC, Bhimnathwala H, Bogusky MJ, Buser CA, Culberson JC, Davide J, Ellis-Hutchings M, Fernandes C, Gibbs JB, Graham SL, Hamilton KA, Hartman GD, Heimbrook DC, Homnick CF, Huber HE, Huff JR, Kassahun K, Koblan KS, Kohl NE, Lobell RB, Lynch JJ Jr, Robinson R, Rodrigues AD, Taylor JS, Walsh ES, Williams TM, Zartman CB, J Med Chem. 2002 Jun 6;45(12):2388-409. PMID:12036349

Page seeded by OCA on Wed Jul 2 12:29:06 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1ld8"
Personal tools